Author Archives: admin


How can nanomedicine be applied to cannabis? – Leafly

Imagine a world in which a tiny nanorobot could deliver a specific cannabinoid directly to your endocannabinoid (ECS) receptors. The nanorobot would be thousands of times smaller than the breadth of a human hair and could carry its small cargo inside a single droplet of liquid to deliver it directly to a target cell such as a cancer cell.

Sound far-fetched? It may be closer than you think, because researchers are making great strides in the fascinating field of nanomedicine.

The cannabis plant contains an amazing group of cannabinoids, terpenes, and flavonoids, and scientists are only beginning to unlock the complex pharmacology and potential of these compounds. Combined with nanomedicine, cannabis has even more potential to treat disease and provide overall health benefits for people.

Related

Scientists can manipulate substances on an atomic scale, in the range of 1-100 nanometers, or one thousand times thinner than a sheet of paper. According to the US Nanotechnology Initiative, substances on the nanoscale have very different properties than bulk substances dounique properties like better electrical conductance, higher strength, and different magnetic properties, light reflection, or chemical reactivity. Nanotechnology can be performed on solids, liquids, or gases to unlock these unique phenomena.

For these reason, nanotechnology applications in medicine offer exciting promise and possibilities, especially when applied to cannabis compounds. Many nanotechnology applications are already in usecomputer circuits made from carbon nanotubes allow for far greater computing power, and nanoparticles are already being used in pharmaceuticals to improve absorption.

Researchers work on all kinds of aspects of nanotechnology, such as finding the best substance for nanoparticles, the best shape for a nanoparticle for a specific delivery, and the best transfer mechanisms for specific drugs. Nanoparticles can generate heat, deliver stem cells, be radioactive or metallic, and so much more.

While many applications are still only imagined by scientists, at its full potential, nanotechnology could be the next medical revolution, vastly changing how diseases are detected and treated.

One of the best applications of nanomedicine is in the area of drug delivery, whereby nanoparticles deliver substances directly to specific cells, like diseased cancer cells. Researchers can engineer nanoparticles to be attracted to a diseased cell and limit the ability to bind with and therefore damage healthy cells.

Scientists at MIT and other institutions have successfully used specific nanoparticles to deliver drugs to tumors. Even more interesting is that nanoparticles are developed to work togetherwhile one locates a tumor, another can use the signal from the first to effectively carry the drug to its intended target.

In one interesting application, scientists have created a nanoparticle that looks for hydrogen peroxide present in inflamed tissue, then it releases a drug in that environment to target heart disease.

Related

There is great promise that nanotechnology and cannabinoids can make an impact on diseases like cancer, multiple sclerosis, Parkinsons, diabetes, and a wide range of serious inflammatory diseases.

Nanotechnology can help identify a disease at an early stage, perhaps even when a single cell has gone awry, and then deliver a targeted cannabinoid to correct a cells behavior, thus stopping the disease in its tracks. It may even be possible for a nanorobot to target a specific endocannabinoid receptor to shut down the entire inflammatory process for the betterment of a patient.

Cannabinoid nanodelivery systems have entered the research mainstream, with scientists working on biologically engineered cannabinoids and other nanoparticles to be transported to cells, and by creating nanocarrier transport substances out of metallics or other substances.

Delivery system research also touches on improving bioavailabilitythe rate at which the active substance of a drug enters the bloodstreamas well as improving the physical stability of nanoparticles and optimizing routes of administration, including injection, pills, or sublingual drops.

A nanotechnology-based targeted drug delivery system can be formulated to deliver cannabinoids directly to endocannabinoid receptors, where the magic happens. Cannabinoids can be packed inside a nanoparticle and carried to its intended target without degradation and with a controlled release.

Related

For example, nanoemulsions are already used in the food industry to deliver probiotics or other bioactive ingredients in a very controlled release. These nanoemulsions use a combination of two liquids that dont normally combinesuch as oil and waterto serve as a barrier to chemical degradation for the cannabinoid while on its journey through the body.

Other encapsulation methods can help with potency issues by increasing absorption, they can help decrease side effects, and they can help cover a substances bitter taste.

Specific cannabis strains could even have tailored therapeutic profiles, and cannabinoids could be bioengineered to produce enhanced effects.

Scientists envision a superclass of cannabinoid nanocarriers that have potential to treat a wide array of endocannabinoid insufficiency issues and thus a wide variety of diseases.

In one example, researchers are looking at novel ways to deliver substances across the difficult blood-brain barrier. This barrier is the bodys built-in defense mechanism to protect the brain, so the ability to transport substances across it directly affects a treatments efficacy.

To this end, scientists are engineering lipid nanocapsules decorated with minute cannabinoids like CBD as novel therapies for diseases of the central nervous system.

Related

Nanotechnology has already transformed drug delivery in profound ways, and cannabinoid delivery is part of this exciting future. There are challenges, of course. Cannabinoids quickly degrade in water and are susceptible to other kinds of degradation, and that presents delivery issues.

More recent discoveries, including the decoding of the cannabis genome, discovery of the main CB1R and CB2R receptors within the human endocannabinoid system (ECS), and discovery of other receptors, are also foundational efforts that contribute to cannabinoid nanotechnology.

The latest research shows great progress in the formulation of targeted cannabinoid-nanocarrier delivery systems, and as such may provide key therapies particularly for central nervous system disorders. As scientists continue to make improvements in both bio-efficacy and bioavailability, cannabis nanotechnology represents an exciting and brave new world.

Read more:
How can nanomedicine be applied to cannabis? - Leafly

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market: Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors…

In this report, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601860&source=atm

The key players covered in this study Orange County Hair Restoration Center Hair Sciences Center of Colorado Anderson Center for Hair Evolution Hair Loss Institute Savola Aesthetic Dermatology Center Virginia Surgical Center Hair Transplant Institute of Miami Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into Platelet Rich Plasma Injections Stem Cell Therapy Market segment by Application, split into Dermatology Clinics Hospitals

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players. To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601860&source=atm

The study objectives of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report are:

To analyze and research the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601860&licType=S&source=atm

See the article here:
Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market: Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors...

Bunk: Company Sells Personalized Embryonic Stem Cells …

This front page story in the SF Chronicle, byline Bernadette Tansey, needs comment.

A San Carlos startup is offering to create personalized stem cells from the spare embryos of fertility clinic clients on the chance that the cells, frozen and stored away, may some day help a family member benefit from medical breakthroughs. The novel business plan of StemLifeLine Inc.which started promoting its service to fertility patients earlier this year as insurance for the futureset off a flash fire of protest from stem cell research opponents and supporters alike. The outcry from anti-abortion groups wasnt surprisingBut some of the most fervent denunciations of StemLifeLine came from vigorous supporters of embryonic stem cell research. Two Stanford University critics aired their complaints in newspaper editorial pages. A prominent Stanford ethicist challenged UC San Francisco scientists who are advisers of the company to sever those ties. These critics accuse StemLifeLine of trying to profit from the promise of stem cell research in the present, even though the work may not yield medical treatments for decades, if ever. These companies are essentially taking advantage of peoples ignorance and fears to make a buck, said David Magnus, director of the Stanford Center for Biomedical Ethics.

Well, waddya know: Accurate reporting and a proper response to this nonsense from the scientists and bioethicists. I would add that embryonic stem cells from a fertilized embryo would never be personalized because the genetic makeup of the embryo was unique to the embryo. Parents or siblings using the stem cells might still need immune response suppressing drugs. Also, ES cells cause tumors. Also, where was Magnus, who states in the story that these treatments might not be available for thirty or forty years, during the passage of Proposition 71 and Amendment 2? Somehow that truth never got into the ads or puff piece media stories.

So, lets be clear here: The reason companies such as thiswhich is charging $7000 to make the cell line and $350 a year for storageis able to sucker people into destroying their own offspring for their own hoped-for medical benefit, is that the scientists hyped this research to the hilt to pass Proposition 71 and destroy the Bush funding policy. If consumers are confused, they and their media and politician camp followers deserve the blame for the confusion.

But good on Tansey for a well-reported story. True, she mentioned it might provide a cure for Alzheimers, which is almost surely wrong. But unlike so many of her colleagues she did a good good job of getting the science and the politics right.

Follow this link:
Bunk: Company Sells Personalized Embryonic Stem Cells ...

Cell Banking Outsourcing Market Size 2020 Industry Share, Strategies, Growth Analysis, Regional Demand, Revenue, Key Players and 2026 Forecast…

The recent report on GlobalCell Banking Outsourcing Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 offered by Credible Markets, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Cell Banking Outsourcing Market.

Impact of Covid-19 in Cell Banking Outsourcing Market:The utility-owned segment is mainly being driven by increasing financial incentives and regulatory supports from the governments globally. The current utility-owned Cell Banking Outsourcing are affected primarily by the COVID-19 pandemic. Most of the projects in China, the US, Germany, and South Korea are delayed, and the companies are facing short-term operational issues due to supply chain constraints and lack of site access due to the COVID-19 outbreak. Asia-Pacific is anticipated to get highly affected by the spread of the COVID-19 due to the effect of the pandemic in China, Japan, and India. China is the epic center of this lethal disease. China is a major country in terms of the chemical industry.

For Better Understanding, Download FREE Sample Copy of Cell Banking Outsourcing Report @https://www.crediblemarkets.com/sample-request/cell-banking-outsourcing-market-391069

A cell bank is a facility that stores cells of specific genome for the purpose of future use in a product or medicinal needs. They often contain expansive amounts of base cell material that can be utilized for various projects. Cell banks can be used to generate detailed characterizations of cell lines and can also help mitigate cross-contamination of a cell line. Utilizing cell banks also reduces the cost of cell culture processes, providing a cost-efficient alternative to keeping cells in culture constantly. Cell banks are commonly used within fields including stem cell research and pharmaceuticals, with cryopreservation being the traditional method of keeping cellular material intact. Cell banks also effectively reduce the frequency of a cell sample diversifying from natural cell divisions over time. Cells mainly used in the regenerative medicine production. Increasing demand of stem cell therapies and number of cell banks expected to boost the global market.

Cell banking is a process of replicating and storing cells for the purpose of future use. Storage of these cell samples can be utilized for research purposes and for surgical reconstruction of damaged body structures. Cells are frozen in cryovials at -196 degrees Celsius along with cryoprotection agents such as 10% solution of DMSO. Cell banking is most commonly used in stem cell research and therapy.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Cell Banking Outsourcing market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Cell Banking Outsourcing industry.

Based on our recent survey, we have several different scenarios about the Cell Banking Outsourcing YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 5860.8 million in 2019. The market size of Cell Banking Outsourcing will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cell Banking Outsourcing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cell Banking Outsourcing market in terms of revenue.

Players, stakeholders, and other participants in the global Cell Banking Outsourcing market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Cell Banking Outsourcing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cell Banking Outsourcing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cell Banking Outsourcing market.

The following players are covered in this report:

SGS Life Sciences

Lonza

CCBC

Vcanbio

AMAG Pharmaceuticals

ViaCord

Thermo Fisher

Wuxi Apptec

CordLife

Esperite

Reliance Life Sciences

Lifecell

Cryo-Cell

Toxikon

Goodwin Biotechnology

Texcell

Cryo Stemcell

Cell Banking Outsourcing Breakdown Data by Type

Stem Cell Banking

Non-stem Cell Banking

Cell Banking Outsourcing Breakdown Data by Application

Cell Bank Storage

Bank Characterization and Testing

Cell Bank Preparation

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Direct Purchase this Report @https://www.crediblemarkets.com/reports/purchase/cell-banking-outsourcing-market-391069?license_type=single_user

Some Points from Table of Content

Global Cell Banking Outsourcing Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Chapter 1 Report Overview

Chapter 2 Global Growth Trends by Regions

Chapter 3 Competition Landscape by Key Players

Chapter 4 Breakdown Data by Type (2015-2026)

Chapter 5 Cell Banking Outsourcing Breakdown Data by Application (2015-2026)

Chapter 6 North America

Chapter 7 Europe

Chapter 8 China

Chapter 9 Japan

Chapter 10 Southeast Asia

Chapter 11 India

Chapter 12 Central & South America

Chapter 13 Key Players Profiles

Chapter 14 Analysts Viewpoints/Conclusions

Chapter 15 Appendix

Grab Maximum Discount on Cell Banking Outsourcing Market Research Report @https://www.crediblemarkets.com/discount-request/cell-banking-outsourcing-market-391069

The research provides answers to the following key questions:

What is the expected growth rate of the Cell Banking Outsourcing market? What will be the market size for the forecast period, 2020 2026?

What are the major driving forces responsible for transforming the trajectory of the industry?

Who are major vendors dominating the Cell Banking Outsourcing industry across different regions? What are their winning strategies to stay ahead in the competition?

What are the market trends business owners can rely upon in the coming years?

What are the threats and challenges expected to restrict the progress of the industry across different countries?

What are the key opportunities that business owners can bank on for the forecast period, 2020 2026?

Browse complete Cell Banking Outsourcing report description And Full TOC @https://www.crediblemarkets.com/reports/cell-banking-outsourcing-market-391069

About Credible Markets

Credible Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have collaborated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.

Ask for customization @https://www.crediblemarkets.com/custom-research

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Website: https://www.crediblemarkets.com

Credible Market Press Releases @https://www.crediblemarkets.com/press_releases

See more here:
Cell Banking Outsourcing Market Size 2020 Industry Share, Strategies, Growth Analysis, Regional Demand, Revenue, Key Players and 2026 Forecast...

Annual Luau and Legends of Surfing Invitational to make virtual waves – For the first time ever surfers scientists physicians and survivors will come…

On. Aug. 19, Dane Perlee rides a wave during the Luau & Legends of Surfing Invitational. PHOTOSBYJOHNCOCOZZA

For the first time ever, surfers, scientists, physicians and survivors will come together virtually to support the fight against cancer at the annualLuau and Legends of Surfing Invitationalon Aug. 9.

As UC San Diego events are being canceled or postponed because of the coronavirus pandemic, the annual fundraiser has transitioned to a virtual format to allow participants to support the fight against cancer from home.

Instead of surfing the ocean, participants are invited to surf the wave of cancer research as theyCrowdsurf for a Cure, helping raise money for research, education and clinical care. All proceeds from the 27th annual Luau and Legends of Surfing Invitational will benefit Moores Cancer Center at UC San Diego Health and contribute to the Campaign for UC San Diego.

As we celebrate the 27th Luau and Legends of Surfing Invitational, it is inspiring to see the local community continue to support the breakthrough discoveries and life-saving treatment developed by Moores Cancer Center, said Dr. Scott M. Lippman, director of Moores Cancer Center at UC San Diego Health. While we cannot join together in person for this years event, cancer does not stop during the COVID-19 pandemic and neither does our commitment to finding new cures and treatments for this life-threatening disease. Thanks to the generous donations raised through the Luau, we can continue to provide our patients with the latest individualized treatment and excellence in patient care that is only available at an academic medical center like ours.

The beloved fundraiserwhich has traded tuxedos for wet suits and ballrooms for beach views since its founding in 1993has brought in nearly $10 million for research and helped thousands of cancer patients through clinical trials, new treatments and delivering discoveries. Now, amid nationwide pandemic-related disruptions to the health sector, support towards ending this devastating disease continues to be critical.

For myelofibrosis patient and advocate Sandra Dillon, this support made all the difference in her journey with cancer. When doctors discovered a small lump behind Dillons ribcage in 2004which turned out to be an enlarged spleen, a symptom of myelofibrosisit came completely out of the blue. As a healthy 28-year-old, the last thing she expected was to be diagnosed with an extremely rare cancer with no real treatment options and a median survival rate of five to seven years.

What I thought was my whole life ahead of me was now just a few years, said Dillon, whose doctors tried to manage her symptoms as she slowly got sicker from the disease. I had such a hard time with my diagnosis and my experience. Knowing that there was no treatment that could stop myelofibrosis, I just didn't want to see doctors, be in a hospital or take any more tests. I kind of gave up on medicine in general and figured, Well, Ill just take the time that I've got left and that's all I've got.

Several years later, the trajectory of Dillons life changed completely when she moved to San Diego and was introduced to the team at Moores Cancer Center. Ridden with fear and hesitancy, she made the courageous decision to continue to fight for her life with support from her friends and husband, Casey Turk.

What I found at Moores Cancer Center was the exact opposite of what I was expecting. I was greeted with so much compassion and care at every level, said Dillon, who came to the center in 2011. Initially, I was afraid of being a pin cushion and just a number passing through a system. Instead, I found a home. Moores Cancer Center is a shining light of what treatment and health care can, and should, look like.

At Moores Cancer Center, Dillon met physician-scientistDr. Catriona Jamieson, Deputy Director of Moores, who enrolled her in a clinical trial for a new drug called fedratinib designed to block cancer cell proliferation. The results were amazingin a few months, Dillon was revitalized with newfound energy, less pain and a whole new life.

However, when the promising cancer drug was discarded for safety concerns and its trial pulled, Jamieson and her team were forced to turn to alternate trials and treatments to halt Dillons disease. With the health of multiple patients depleting in the absence of fedratinib, Jamieson worked tirelessly alongside scientist, biotech executive and Moores Cancer Center Board Vice Chair John Hood, who has a doctorate in medical physiology and led early research on the drug, to fight to bring it back. When fedratinib was finally approved by the FDA in 2019, it was the first new therapy approved for myelofibrosis in nearly a decade. It is now available under the brand name Inrebic.

Now that I am on the drug, I havent had to have a blood transfusion in over a year. I feel incredible again, said Dillon. What Dr. Jamieson and Hood have accomplished is incredibleits a blessing for me and an amazing testament to what is possible.

During the online fundraiser on Aug. 9, Jamieson and Hood will both be recognized with the Rell Sunn Award, which honors the memory of Rell Kapoliokaehukai Sunn, known as the First Lady of Surfing. Sunn was diagnosed with breast cancer at the age of 32, but rather than submitting to the disease, she lived life to the fullest until passing 15 years later in 1998. The Rell Sunn Award recognizes individuals who have made a difference in the battle against cancer and who embody the Aloha spirit.

This event has had a sustainably positive impact on our relentless drive to deliver new discoveries to the clinic with alacrity, and our unique capacity at Moores Cancer Center to develop personalized cancer stem cell, immunotherapy, and precision-medicine-guided targeted therapies for hopeful patients across economic strata, said Jamieson. To receive this award is such an extraordinary privilege considering that it honors Rell Sunn, a champion Hawaiian surfer who battled breast cancer and was the personification of hope, joy and the spirit of ganbatte, which is the Japanese word for never, ever, ever, give up.

Being honored based on a person like Sunn, by your peers and neighbors, is incredible. I feel very grateful for it, said Hood. I hope what we didfacing down the FDA with a small group in the company and doing everything we can to get it to the patientswould make her proud.

The virtual luau festivities kick off online on Aug. 9 at 5 p.m. Guests can expect to enjoy a program featuring: an address from Chancellor Pradeep K. Khosla, Vice Chancellor for Health Sciences Dr. David Brenner and CEO of UC San Diego Health Patty Maysent, messages from surf legends, Moores Cancer Center leaders, Polynesian dancers, live music and more. Attendees in the local region can also join in by pre-ordering aDinner and Drinks packagea catered meal and cocktails with options to be picked up or delivered to their home to enjoy during the event. Featured artwork will be presented by Southern California surfer Andy Davis.

The Luau and Legends of Surfing Invitationals Crowdsurf for a Cure is free to register and to attend. Event sponsors include: Cooley LLP; Lina and Christian Waage; Lisa and Mike Rhodes; Valerie Ewell Armstrong and Sam Armstrong; BioMed Realty; ASML; Arey Jones; The Allergan Foundation; and Pfizer. For more information about sponsorship opportunities and event activities,visit the Luau and Legends of Surfing Invitational website. You can also get read more about theMoores Cancer Center at UC San Diego Health.

Gifts made through the 27th annual Luau and Legends of Surfing Invitationals Crowdsurf for a Cure also contribute to the Campaign for UC San Diegoa university-wide comprehensive fundraising effort concluding in 2022. Alongside UC San Diegos philanthropic partners, the university is continuing its nontraditional path toward revolutionary ideas, unexpected answers, lifesaving discoveries and planet-changing impact. For more information,visit campaign.ucsd.edu.

More here:
Annual Luau and Legends of Surfing Invitational to make virtual waves - For the first time ever surfers scientists physicians and survivors will come...

Ozzy Osbourne: I was convinced I was dying during nightmare health year – Dothan Eagle

Ozzy Osbourne was "convinced" he was dying amid his year plagued with health setbacks.

The 'Crazy Train' hitmaker suffered a nightmare year in 2019 which saw him endure several medical issues including a fall, neck surgery, an infection in his hand, and hospitalization for the flu.

And at the start of 2020, he revealed he had been diagnosed with Parkinson's - which is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination - for which he later had stem cell treatment to try and ease the symptoms.

Discussing his year of ill health, Ozzy said: "I'm not back to 100 percent. I'm about 75 percent there, but it's such a slow recovery. Spine surgery is bad news, man. I've been in such a bad state with pain; I'm still having a lot of pain.

"There was a point I was convinced that I was dying. I was in that much discomfort and pain and misery. I thought they were all hiding it from me. I remember saying to Sharon, 'You've gotta level with me. Is it worse than you're making it out [to be]?' She says, 'No.' ... I've dropped all the medication for pain now."

And despite his health woes, the 71-year-old rocker is itching to get back on stage as soon as the coronavirus pandemic - which has forced all concerts to be cancelled - has passed.

He added in an interview for SiriusXM: "I cannot wait [to get on stage], but I was talking to Tony Iommi the other day, and he was saying with the way it's going with this coronavirus, indoor shows will be a thing of the past."

Follow this link:
Ozzy Osbourne: I was convinced I was dying during nightmare health year - Dothan Eagle

Stem Cell Therapy Market Is Forecasted To Register A CAGR Growth Of XX% Between And2020 – Bulletin Line

With having published myriads of reports, PMR imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, PMR serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Stem Cell Therapy market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Stem Cell Therapy market.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3253

The Stem Cell Therapy market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

Prominent players operating in the Stem Cell Therapy market players consist of the following:

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

Key points covered in the report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3253

What does the Stem Cell Therapy market report contain?

Readers can get the answers of the following questions while going through the Stem Cell Therapy market report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3253

Go here to read the rest:
Stem Cell Therapy Market Is Forecasted To Register A CAGR Growth Of XX% Between And2020 - Bulletin Line

MediVet Biologics Rebrands as Ardent Animal Health – Benzinga

LEXINGTON, Ky., Aug. 3, 2020 /PRNewswire-PRWeb/ -- Introducing Ardent Animal Health MediVet Biologics rebrands company and positions its platform of innovative products for transformative growth

MediVet Biologics is announcing a new name and a new look for its corporate brand as it relaunches itself as Ardent Animal Health.

In the years since its inception in 2016, the new Ardent Animal Health has developed into a global leader in the areas of veterinary regenerative medicine and oncology solutions for animals. The company's core mission is to develop affordable, innovative treatments for animal cancer and disease while supporting its veterinary partners in their efforts to make a positive impact on pet health.

"The name 'Ardent' captures the spirit of our organization as a company with fiery passion for innovation guided by compassion for the well-being of animals. The new brand translates the enormous and unique impact our veterinarian customers make each day in the lives of their patients. Our aim is to leverage our brand to accelerate connecting pet owners seeking advanced care to our expanding network of progressive veterinarian partners around the world," says Thomas Masterson, President of Ardent Animal Health.

Under its former brand of MediVet Biologics, Ardent Animal Health developed the first in-clinic adipose regenerative stem cell therapy kit, ActiStem Therapy. A major scientific advancement in animal regenerative medicine, the product offers an economic solution for owners of pets suffering from osteoarthritis, hip dysplasia, and ligament and cartilage injuries, as well as numerous mobility ailments. In addition to regenerative cells from fat, Ardent-certified hospitals offer other biologic treatments such as Platelet Rich Plasma, or PRP, a blood-derived treatment gaining popularity in human sports medicine.

Ardent Animal Health is unique for a company of its size, as it has surrounded its current and pipeline products with strong intellectual property and multiple collaborative university studies. This has allowed the company to grow, cementing its current technology, and look toward the future for its stem cell-based product pipeline candidates. Ardent Animal Health will launch with an extensive following of pet owners and veterinarians positively impacted by its products and services. The studies, passionate customers, and patient outcomes continue to provide momentum for the company's technology and products. Over 20,000 veterinary patients have received treatment of an Ardent Animal Health regenerative product or service.

Ardent Animal Health has also introduced cutting edge science to fight against canine cancer with its cancer vaccine service, K9- ACV, an immunotherapy vaccine generated from a canine patient's own cancerous tumor. K9-ACV is designed to stimulate the canine patient's immune response to attack the cancer. "We are looking to meet an unmet need in pet cancer, at the family veterinarian office when needed. 50% of dogs over the age of ten will develop some type of cancer, so there is a need for a broadly applicable approach that can improve lifespan at a reasonable cost. Our preliminary studies and extensive market research indicate this approach will provide access to pets that need it," Masterson said.

According to Mr. Masterson, the company's strength in these core innovative therapeutic areas will allow the organization to accelerate growth following its recent transition in both leadership and ownership. As a portfolio company of STUCK Fund 1, based in Milwaukee, WI, Ardent Animal Health will continue to develop novel approaches for early disease detection and treatments, with a focus on precision medicine for pets in need.

"We will continue to focus much of our strategy in creating novel products and services utilized in veterinary hospitals. We believe that this approach is key to the future of animal health. It is important not only for value creation but to ensure veterinarians have the ability to diagnose and treat their patients with the same leading-edge strategies underway in human health. Our animal family members deserve it."

Disclaimer Experimental Cancer Vaccines created by Ardent Animal Health are provided under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight for use under supervision/prescription of a licensed veterinarian. Safety & efficacy have not been yet established.

About Ardent Animal Health

Since 2016 Ardent Animal Health based near Lexington, KY, has provided advanced medical strategies to veterinary hospitals around the world. Ardent provides regenerative medicine treatments such as ActiStem Therapy and PureVet PRP to veterinarians for pain and disease in companion and equine patients. Additionally, Ardent Animal Health is pursuing advanced strategies for detection and treatment of canine cancer. Through creation of its own intellectual property and strategic licensing partners, the company's portfolio includes current and future offerings aimed to raise the standard for animal healthcare.

Home

About STUCK Fund 1

Ardent Animal Health represents an innovation-focused element of the STUCK Fund 1 portfolio, as Ardent competes in the fast-growing and recession-resistant pet health sector. STUCK Fund 1, based in Milwaukee, WI, was founded in 2014 to live out the lessons the investment firm's founders learned from growing its business into an international, $100 million organization. STUCK founders were honored with numerous accolades in their prior ventures, including the Muskego Manufacturing Business of the Year award and the Waukesha Business Alliance Manufacturing Business of the Year honor, among several others. Currently, the investment firm supports like-minded entrepreneurs to accelerate and sustain the growth of their businesses.

About

Media Contact: Matt Yeich (859)885-7111 matt@ardentanimalhealth.com

SOURCE Ardent Animal Health

See the original post:
MediVet Biologics Rebrands as Ardent Animal Health - Benzinga

Automated Cell Culture Systems Market to Record Strong Growth due to High Demand for Advanced Treatment of Chronic Conditions, Future Market Insights…

Dubai, U.A.E, Aug. 3, 2020 /PRNewswire/ -- According to Future Market Insights, the automated cell culture systems marketwill exhibit a strong CAGR of 8% from 2020-2030.

Escalating incidences of chronic ailments have spurred greater research in cytology and cell biology for developing advanced diagnosis and treatment. This is largely an end-product of boundaries in conventional pharmaceuticals. Furthermore, growing complexities of the nature of chronic diseases is prompting various technological advancements with regard to treatment, thereby bolstering the scope of automated cell culture systems.

Greater penetration of 3D-cell cultures have significantly boosted the adoption of automated culture systems, as is the need for faster testing of biological or biochemical activities. Furthermore, requirement of cell lines to devise vaccines for COVID-19 shall catapult the automated cell culture market in the upcoming forecast period.

"Key players are developing specific and specialty growth media with the aid of various technological advancements, which is expected to sustain market growth over the following decade," infers an FMI analyst.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-7860

Key Takeaways from FMI's Automated Cell Structure Systems Report

Automated Cell Culture Systems Market- Key Trends

Automated Cell Culture Systems Market- Region-wise Analysis

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-7860

Automated Cell Culture Systems Market- Competitive Landscape

Prominent players are concentrating on offering new products, innovations and collaborations with other companies to widen their outreach across major geographical areas.

For instance, in July 2020, Sphere Fluidics announced a partnership with the Heriot-Watt University in Edinburgh for developing next generation droplet generator instrumentation. This agreement is for expanding its advanced biologics discovery and therapeutic cell line development.

Also, in February 2020, Selexis announced the application of Bioprocessing 4.0 by incorporating automated systems such as the ambr and Beacon optofluidic platforms for enhanced cell line development.

Request special price for this Report to our Sales [emailprotected]https://www.futuremarketinsights.com/request-special-price/rep-gb-7860

Automated Cell Culture Systems Market Taxonomy

Product Type

Cell Culture Type

Application

End User

Region/Country

Request the Coronavirus Impact Analysis across Industries and [emailprotected]https://www.futuremarketinsights.com/covid19/rep-gb-7860

More Insights on the Automated Cell Culture Systems Market

The study provides compelling insights on automated cell culture systems market on basis of product type (automated cell culture storage equipment, automated cell culture vessels, bioreactors and consumables), cell culture type (finite cell line cultures, infinite cell line cultures), application (drug development, stem cell research, regenerative medicine and cancer research) and end user (biotech companies, research organizations, academic institutes), and across seven major regions.

Explore Extensive Insights on FMI's Healthcare, Pharmaceuticals and Medical Devices Landscape

Fertility and Pregnancy Rapid Test Kits Market: Investigate a detailed bird's-eye view of FMI's fertility and pregnancy rapid test kits market by perusing the report for the upcoming decade's forecast period, bringing to the fore valuable insights responsible for shaping the growth trajectory during the forecast.

Home Healthcare Market: A surging geriatric population pool is leading to an increase in the prevalence of chronic disorders, ultimately boosting the need for home healthcare products in recent years, concludes FMI on its report on the home healthcare market for the 2020-2030 assessment period.

Gene Synthesis Market: The gene synthesis market study published by FMI incorporates a global industry analysis from 2014-2018 and opportunity assessment from 2019-2029, delivering a comprehensive outlook on prominent growth dynamics.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries.FMIisheadquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latestmarket research reportsandindustry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

ContactMr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: [emailprotected] For Media Enquiries: [emailprotected]Report: https://www.futuremarketinsights.com/reports/automated-cell-culture-systems-market Press Release Source:https://www.futuremarketinsights.com/press-release/automated-cell-culture-systems-market

SOURCE Future Market Insights

Follow this link:
Automated Cell Culture Systems Market to Record Strong Growth due to High Demand for Advanced Treatment of Chronic Conditions, Future Market Insights...

CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research – PRNewswire

LANCASTER, Calif., Aug. 3, 2020 /PRNewswire/ -- R. Rex Parris, President and Chairman of the Board of biotech company CarthroniX, announced a donation of $50,000 to Denis Evseenko, MD, Ph.D. of the Keck School of Medicine of USC to support continued research in the field longevity.

Dr. Evseenko was recently awarded a $1.69 million research project grant from the National Institutes of Health to address how to slow arthritis in aging joints. He has helped develop breakthroughs in molecular studies that identified and characterized the unique cell populations that form the superficial human joint cartilage zone.

Dr. Evseenko is one of the world's leading medical researchers of arthritis and how gene activity drives cartilage development. "The CDC reports that 23% of all adults, or 54 million people, have some form of arthritis and are limited in their activities due to severe joint pain," said Mr. Parris. "Dr. Evseenko's work will help tens of millions of people in this country and many more worldwide, living with arthritis's daily struggle. Now there is evidence that it will also extend the quality of life and longevity."

CarthroniX is comprised of scientists and surgeons with expertise in regenerative medicine and stem cell research. Their research is focused on creating novel small molecules to stimulate the regrowth of healthy cartilage. Dr. Evseenko's work fits seamlessly with CarthroniX's goals of extending the quality of life for millions of people. Osteoarthritis is one component of the aging process as cartilage degenerates over time, especially after injury and wear and tear.

Recently it was discovered that some of the small molecules studied to treat arthritis also reverse the aging of human cells in vitro. This gift will enable Dr. Evseenko's lab to advance to the next stage of research. The CX-1 small molecule will hopefully slow the aging of mice. If this is confirmed, CarthroniX will seek FDA approval of human trials to investigate CX-1's effect on human longevity and regeneration of vital organs. "This gift will help us explore some fundamental and transformative questions related to life span extension," said Dr. Evseenko.

CarthroniX novel technologies are proven to preserve, repair, and regenerate cartilage in joints and suppress inflammation in large animals. CarthroniX is developing two types of drugs: one that is both regenerative and anti-inflammatory, and a second that is solely anti-inflammatory.

ABOUT CarthroniX

CarthroniX is developing novel small molecules to stimulate the growth and regeneration of articular cartilage in joints. CarthroniX patented, first-in-class small molecule CX-1 activates an established regenerative pathway; they demonstrated this results in cartilage proliferation, cellular migration, and deposition of cartilaginous matrix.

Media Contact: Joe Marchelewski, [emailprotected]

SOURCE PARRIS Law Firm

Originally posted here:
CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire